热门资讯> 正文
CVRx股价上涨,CMS纳入Barostim植入手术
2025-07-17 04:08
- CVRx (NASDAQ:CVRX) saw a 17% increase in its shares following the announcement that Centers for Medicare and Medicaid Services (CMS) has proposed to include the Barostim implant procedure.
- The procedure is included under the New Technology Ambulatory Payment Classification 1580, which would provide around $45,000 for outpatient procedures.
- Additionally, CMS is seeking feedback on the potential need for a Level 6 Neurostimulator APC.
- This proposal comes after two other favorable updates regarding reimbursement rates in the past nine months.
More on CVRx
- CVRx: Sell-Off Ignores Its True Potential
- CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript
- CVRx downgraded at J.P. Morgan after Q1 sales miss
- Seeking Alpha’s Quant Rating on CVRx
- Historical earnings data for CVRx
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。